Silk fibroin-based nanotherapeutics: application in the treatment of colonic diseases

The incidence of colonic diseases (e.g., inflammatory bowel diseases and colon cancer) is rapidly rising. Nanotherapeutic has been considered as a promising strategy in the treatment of colonic diseases. Silk fibroin (SF) has been widely used as a drug-carrier matrix. Interestingly, SF-based nanoparticles (SFNPs) have intrinsic anti-inflammatory activity, wound healing capacity and lysosomal environment-responsive drug-release property. With further investigations, the sequences of SF molecules could be precisely modified through chemical reactions or transgenic techniques to greatly improve the properties of SFNPs. Here, we review recent advances in the application of SFNPs toward the treatment of colonic diseases. We also discuss future developments that might improve the anti-inflammatory and anti-colon cancer activities of SF-based nanotherapeutics.

Download Full-text

Role of MicroRNAs in Colon Cancer Progression and Metastasis

Endocrine Metabolic & Immune Disorders - Drug Targets ◽

10.2174/1871530320666200825184924 ◽

2020 ◽

Vol 20 ◽

Author(s):

Shruthi Sanjitha Sampath ◽

Sivaramakrishnan Venkatabalsubramanian ◽

Satish Ramalingam

Keyword(s):

Colon Cancer ◽

Cancer Progression ◽

Target Genes ◽

Tumour Progression ◽

Intestinal Barrier ◽

Colon Cancer Progression ◽

Bowel Diseases ◽

Inflammatory Bowel ◽

Novel Therapeutic Strategies

: MicroRNAs regulate gene expression at the posttranscriptional level by binding to the mRNA of their target genes. The dysfunction of miRNAs is strongly associated with the inflammation of the colon. Besides, some microRNAs are shown to suppress tumours while others promote tumour progression and metastasis. Inflammatory bowel diseases include Crohn’s disease and Ulcerative colitis which increase the risk factor for inflammation-associated colon cancer. MicroRNAs are shown to be involved in gastrointestinal pathologies, by targeting the transcripts encoding proteins of the intestinal barrier and their regulators that are associated with inflammation and colon cancer. Detection of these microRNAs in the blood, serum, tissues, faecal matter, etc will enable us to use these microRNAs as biomarkers for early detection of the associated malignancies and design novel therapeutic strategies to overcome the same. Information on MicroRNAs can be applied for the development of targeted therapies against inflammation-mediated colon cancer.

Download Full-text

Cannabis and Canabidinoids on the Inflammatory Bowel Diseases: Going Beyond Misuse

International Journal of Molecular Sciences ◽

10.3390/ijms21082940 ◽

2020 ◽

Vol 21 (8) ◽

pp. 2940

Author(s):

Antonelly Cassio Alves de Carvalho ◽

Gabriela Achete de Souza ◽

Samylla Vaz de Marqui ◽

Élen Landgraf Guiguer ◽

Adriano Cressoni Araújo ◽

...

Keyword(s):

Quality Of Life ◽

Inflammatory Bowel Diseases ◽

Literature Search ◽

Cannabis Sativa ◽

Antioxidant Properties ◽

Number Of Patients ◽

Bowel Diseases ◽

Inflammatory Bowel ◽

Anti Inflammatory

Inflammatory bowel diseases (IBD) are characterized by a chronic and recurrent gastrointestinal condition, including mainly ulcerative colitis (UC) and Crohn’s disease (CD). Cannabis sativa (CS) is widely used for medicinal, recreational, and religious purposes. The most studied compound of CS is tetrahydrocannabinol (THC) and cannabidiol (CBD). Besides many relevant therapeutic roles such as anti-inflammatory and antioxidant properties, there is still much controversy about the consumption of this plant since the misuse can lead to serious health problems. Because of these reasons, the aim of this review is to investigate the effects of CS on the treatment of UC and CD. The literature search was performed in PubMed/Medline, PMC, EMBASE, and Cochrane databases. The use of CS leads to the improvement of UC and CD scores and quality of life. The medical use of CS is on the rise. Although the literature shows relevant antioxidant and anti-inflammatory effects that could improve UC and CD scores, it is still not possible to establish a treatment criterion since the studies have no standardization regarding the variety and part of the plant that is used, route of administration and doses. Therefore, we suggest caution in the use of CS in the therapeutic approach of IBD until clinical trials with standardization and a relevant number of patients are performed.

Download Full-text

IL-23 in inflammatory bowel diseases and colon cancer

Cytokine & Growth Factor Reviews ◽

10.1016/j.cytogfr.2018.12.002 ◽

2019 ◽

Vol 45 ◽

pp. 1-8 ◽

Cited By ~ 30

Author(s):

Markus F. Neurath

Keyword(s):

Colon Cancer ◽

Inflammatory Bowel Diseases ◽

Bowel Diseases ◽

Inflammatory Bowel

Download Full-text

Transmembrane serine protease 2 and angiotensin-converting enzyme 2 anti-inflammatory receptors for COVID-19/inflammatory bowel diseases treatment

World Journal of Gastroenterology ◽

10.3748/wjg.v27.i46.7943 ◽

2021 ◽

Vol 27 (46) ◽

pp. 7943-7955

Author(s):

Naser-Aldin Lashgari ◽

Nazanin Momeni Roudsari ◽

Saeideh Momtaz ◽

Amir Hossein Abdolghaffari

Keyword(s):

Angiotensin Converting Enzyme ◽

Serine Protease ◽

Inflammatory Bowel Diseases ◽

Converting Enzyme ◽

Angiotensin Converting Enzyme 2 ◽

Bowel Diseases ◽

Inflammatory Bowel ◽

Anti Inflammatory ◽

Transmembrane Serine Protease

Download Full-text

Meta-Analysis of IBD Gut Samples Gene Expression Identifies Specific Markers of Ileal and Colonic Diseases

Inflammatory Bowel Diseases ◽

10.1093/ibd/izab311 ◽

2021 ◽

Author(s):

Kevin Perez ◽

Marjolaine Ngollo ◽

Keren Rabinowitz ◽

Nassim Hamoudi ◽

Philippe Seksik ◽

...

Keyword(s):

Gene Expression ◽

Meta Analysis ◽

Mucosal Inflammation ◽

Colonic Diseases ◽

Ileal Mucosa ◽

Bowel Diseases ◽

Tissue Damages ◽

Inflammatory Bowel ◽

Disease Stratification ◽

Disease Location

Abstract Background Inflammatory bowel diseases (IBDs) are characterized by chronic inflammation and tissue damages in limited segments of the digestive tract. Pathogenesis in the tissue and mucosal inflammation probably differs according to disease location. Our aim was to further analyze transcriptomic profiles in different locations of IBD, differentiating ulcerative colitis (UC), colonic Crohn’s disease (CD), ileal CD, and pouchitis, with respect to normal colonic and ileal mucosa. We thus performed a meta-analysis focusing on specific transcriptomic signatures of ileal and colonic diseases. Methods We identified 5 cohorts with available transcriptomic data in ileal or colonic samples from active IBD and non-IBD control samples. The meta-analysis was performed on 1047 samples. In each cohort separately, we compared gene expression in CD ileitis and normal ileum; in CD colitis, UC, and normal colon; and finally in pouchitis and normal ileum. Results We identified specific markers of ileal (FOLH1, CA2) and colonic (REG3A) inflammation and showed that, with disease, some cells from the ileum start to express colonic markers. We confirmed by immunohistochemistry that these markers were specifically present in ileal or colonic diseases. We highlighted that, overall, colonic CD resembles UC and is distinct from ileal CD, which is in turn closer to pouchitis. Conclusions We demonstrated that ileal and colonic diseases exhibit specific signatures, independent of their initial clinical classification. This supports molecular, rather than clinical, disease stratification, and may be used to design drugs specifically targeting ileal or colonic diseases.

Download Full-text

THE ROLE OF ADIPOCYTOKINES IN COLON CANCER AND ADENOMAS / ULOGA ADIPOCITOKINA U KANCERU I ADENOMIMA DEBELOG CREVA

Journal of Medical Biochemistry ◽

10.2478/jomb-2013-0001 ◽

2013 ◽

Vol 33 (2) ◽

pp. 135-142 ◽

Cited By ~ 7

Author(s):

Feti Tulubas ◽

Rafet Mete ◽

Meltem Oznur ◽

Birol Topcu

Keyword(s):

Colon Cancer ◽

Pearson Correlation ◽

Continuous Variables ◽

Colon Adenoma ◽

Bowel Diseases ◽

Inflammatory Bowel ◽

And Control ◽

The Relationship ◽

Insulin Insensitivity

Summary Metabolic changes resulting from obesity, insulin insensitivity, and imbalances in hormones such as adiponectin, leptin, resistin, apelin and visfatin, which are derived from white adipose tissue-derived hormone, are directly linked to both colon cancer (CC) and inflammatory bowel diseases increasing tissue-derived risk. We conducted this study to evaluate the relationship between the circulating concentrations of adiponectin, leptin, resistin, apelin and visfatin and colon adenoma and CC. Our study included 90 participants aged >18 years who were divided into three groups: colon cancer, adenoma and control. The serum concentrations of the investigated adipohormones were measured with ELISA in 30 patients with colon adenoma, 30 with CC and 30 controls with no colon pathology. Demographic, anthropometric, metabolic and hormonal parameters were also recorded. The group means were compared by using one-way analysis of variance (ANOVA). Dual comparisons between groups were analyzed with the Tukey test. Pearson correlation coefficient was used to determine the relation between continuous variables. Adiponectin and leptin levels in patients with adenomas (p<0.000; p<0.000, respectively) and CC (p<0.000; p<0.000, respectively) were lower than in controls. Apelin level in patients with CC (p<0.000; p<0.000, respectively) was lower than in patients with adenomas and in controls. Resistin and visfatin levels in patients with CC (p<0.000; p<0.000, respectively) were higher than in patients with adenomas and in controls.

Download Full-text